Search Results
Your search for ,twO matches 12055 pages
Showing 1851 - 1900SWOG S1801: Addition of Neoadjuvant Pembrolizumab to Adjuvant Pembrolizumab Yields Benefits in High-Risk Resectable Melanoma
In resectable stage III to IV melanoma, three cycles of neoadjuvant pembrolizumab followed by adjuvant pembrolizumab was significantly more beneficial than adjuvant pembrolizumab alone, based on the results of the phase II SWOG S1801 trial presented in a Presidential Symposium at the European...
NICHE-2: ‘Unprecedented’ Waterfall Plot Achieved With Neoadjuvant Immunotherapy in dMMR Colon Cancer
Treatment with neoadjuvant immunotherapy in colon cancer resulted in major pathologic responses in 95% of patients, NICHE-2 investigators reported at the European Society for Medical Oncology (ESMO) Congress 2022.1 Additionally, after 4 weeks of nivolumab plus ipilimumab, 67% of patients with...
Negative Phase III Trials May Dampen Enthusiasm for Immunotherapy in the Adjuvant Setting in Kidney Cancer
Three negative phase III trials presented at the European Society for Medical Oncology (ESMO) Congress 2022 may dampen enthusiasm for immunotherapy as adjuvant therapy for renal cell carcinoma (RCC). None of the three trials—CheckMate 914, IMmotion010, and PROSPER—met its primary endpoint.1-3 The...
RADICALS-HD Trial: Duration of Androgen-Deprivation Therapy With Radiotherapy After Radical Prostatectomy
The addition of 24 months of androgen-deprivation therapy to postoperative radiotherapy after radical prostatectomy provided a metastasis-free survival benefit and improved the time to salvage therapy in patients with prostate cancer, according to the preliminary results from the RADICALS-HD trial...
COSMIC-313: Triplet Therapy Is Active in Renal Cell Carcinoma, but Toxicities Pose a Challenge
The addition of cabozantinib to nivolumab plus ipilimumab prolonged progression-free survival in untreated intermediate-risk patients with advanced renal cell carcinoma (RCC), according to the first results of the phase III COSMIC-313 trial. These findings were presented as a Presidential Symposium ...
Expert Point of View: Mary O’Brien, MD
Formal discussant Mary O’Brien, MD, Head of the Lung Unit, the Royal Marsden Hospital, NHS Foundation Trust, London, commented on the POSEIDON trial. “The POSEIDON trial is the largest data set we have on KRAS-mutated [non–small cell lung cancer], with a positive signal in picking up some patients...
POSEIDON Follow-up Suggests Chemoimmunotherapy Triplet Extends Survival in Difficult-to-Treat NSCLC Mutational Subtypes
After 4 years, a limited course of five cycles of tremelimumab added to durvalumab plus chemotherapy extended overall survival in patients with metastatic non–small cell lung cancer (NSCLC) compared with chemotherapy alone, according to an updated exploratory analysis of the phase III POSEIDON...
IPSOS Trial: Platinum-Ineligible Patients With NSCLC May Gain Survival Benefit From Atezolizumab Therapy
In platinum-ineligible patients with advanced non–small cell lung cancer (NSCLC), first-line treatment with the PD-L1 checkpoint inhibitor atezolizumab improved overall survival by an absolute value of about 1 month but almost doubled the rate of 2-year overall survival compared with chemotherapy...
Expert Point of View: Natasha Leighl, MD
“CodeBreaK 200 clearly establishes sotorasib as the new standard of care, replacing docetaxel as second- or third-line therapy for advanced KRAS G12C–mutated lung cancer,” stated invited discussant Natasha Leighl, MD, of the Princess Margaret Cancer Centre, Toronto. “Sotorasib improved...
Sotorasib: A New Standard of Care for Second- or Third-Line Treatment of KRAS G12C–Mutated NSCLC?
The KRAS G12C inhibitor sotorasib doubled the rate of progression-free survival at 12 months and reduced the risk of disease progression or death by 34% compared with standard second-line docetaxel for patients with previously treated non–small cell lung cancer (NSCLC) and KRAS G12C mutations....
The NordICC Trial: The Devil Is in the Details
Colorectal cancer ranks third among cancer deaths in both men and women in the United States, with an estimated 106,000 new cases and 52,000 deaths anticipated in 2022.1 Colorectal cancer rates have declined by approximately 2% per year from 2014 to 2018 in people over the age of 50 years, which is ...
Longer-Term Follow-up From ADAURA Supports Adjuvant Osimertinib as Standard of Care for EGFR-Mutated Stage IB to IIIA NSCLC
With longer-term follow-up, adjuvant treatment with osimertinib led to a 77% reduction in the risk of disease recurrence or death following complete resection vs placebo-treated patients with EGFR-mutated, stage II to IIIA non–small cell lung cancer (NSCLC). Disease-free survival was improved...
Highlights From the ESMO Congress 2022
At this year’s European Society for Medical Oncology (ESMO) Congress, we experienced an eagerly awaited return to normality (or almost), and the quality of the science on display was anything but disappointing: from molecular medicine to treatment de-escalation, from early cancer detection and...
Researchers Discover Differences in Response to Pembrolizumab Among Patients With Endometrial Cancer
Researchers discovered a differential clinical response to pembrolizumab in patients with Lynch-like (mutated) vs methylated microsatellite instability–high endometrial cancer, outlining characteristics of patients who may derive benefit from immune checkpoint blockade antibodies, according to new...
Legal and Ethical Use of Complementary and Alternative Medicine Interventions in Oncology
In addition to, or instead of, receiving therapies that are the standard of care, patients with cancer sometimes request to receive complementary (therapies used in conjunction with standard cancer treatment) and alternative (nonstandard treatments used in place of standard cancer treatment)...
Neoadjuvant Immunotherapy With Relatlimab and Nivolumab in Stage III Melanoma
The combination of immune checkpoint inhibitors relatlimab and nivolumab for patients with stage III melanoma given before surgery was safe and completely cleared all viable tumor in 57% of patients in a phase II study, according to findings published by Amaria et al in Nature. In addition to...
Addition of Bemarituzumab to mFOLFOX in FGFR2b-Selected Gastric or Gastroesophageal Junction Adenocarcinoma
In the phase II FIGHT trial reported in The Lancet Oncology, Zev A. Wainberg, MD, and colleagues found numerically better progression-free survival with the addition of the anti-FGFR2b antibody bemarituzumab to mFOLFOX (modified fluorouracil, leucovorin, and oxaliplatin) in patients with...
Rogaratinib vs Chemotherapy in Previously Treated Patients With Advanced Urothelial Carcinoma and FGFR1/3 mRNA Overexpression
As reported in the Journal of Clinical Oncology by Cora N. Sternberg, MD, and colleagues, interim analysis of the phase II portion of the phase II/III FORT-1 trial has shown similar objective response rates with the oral FGFR1–4 inhibitor rogaratinib vs chemotherapy in previously treated patients...
FDA Approvals in Hepatocellular Carcinoma and Multiple Myeloma
On this episode, we’re covering two recent approvals from the U.S. Food and Drug Administration (FDA): one in unresectable hepatocellular carcinoma, and one in relapsed or refractory multiple myeloma.
Concurrent Bevacizumab and Reirradiation vs Bevacizumab Alone in Recurrent Glioblastoma
As reported in the Journal of Clinical Oncology by Christina I. Tsien, MD, and colleagues, the phase II NRG Oncology/RTOG1205 trial has shown improved progression-free—but not overall—survival with concurrent bevacizumab and reirradiation vs bevacizumab alone in patients with recurrent...
Continuous Enzalutamide Plus Docetaxel for Patients With Metastatic Castration-Resistant Prostate Cancer With Disease Progression on Enzalutamide
In the European phase IIIb PRESIDE trial reported in The Lancet Oncology, Merseburger et al found that treatment with docetaxel and continuing enzalutamide vs placebo improved progression-free survival in patients with metastatic castration-resistant prostate cancer who had disease progression on...
Expert Point of View: Christian U. Blank, MD, PhD
Christian U. Blank, MD, PhD, Professor of Internal Medicine, staff member at Netherlands Cancer Institute, Professor at the University of Regensburg in Germany, and founding member of the International Neoadjuvant Melanoma Consortium, was the invited discussant of the MD Anderson study of...
Phase II Trial Reports High Response Rates With Neoadjuvant Cemiplimab in Cutaneous Squamous Cell Carcinoma
In an international, multicenter phase II clinical trial, almost two-thirds of patients with stage II to IV cutaneous squamous cell carcinoma had tumors nearly or completely eradicated by neoadjuvant treatment with cemiplimab-rwlc, an agent targeting PD-1. The results were presented at the European ...
2022 Annual Report to the Nation on the Status of Cancer Released
Overall cancer death rates continued to decline among men, women, children, adolescents, and young adults in every major racial and ethnic group in the United States from 2015 to 2019, according to the latest Annual Report to the Nation on the Status of Cancer. From 2014 to 2018, overall cancer...
AACR and ASCO Release Joint Policy Statement on Electronic Nicotine Delivery Systems
The American Association for Cancer Research (AACR) and ASCO have released a joint policy statement outlining the latest research on the use of e-cigarettes and other electronic nicotine delivery systems (ENDS) and recommendations for regulating these products to protect public health. The...
3-Week Course of Radiotherapy With Concurrent Radiation Boost Found to Be Safe and Effective for Patients With Early-Stage Breast Cancer and Elevated Risk of Recurrence
A 3-week course of radiation therapy is as safe and effective as 4 to 6 weeks of treatment for patients with early-stage breast cancer who have a higher risk of having their tumors recur, results of a randomized phase III clinical trial show. Delivering fewer, but higher, doses of radiation...
EXTEND Trial: Metastasis-Directed Radiation Therapy Plus Hormone Therapy May Improve Progression-Free Survival in Patients With Advanced Prostate Cancer
Researchers from The University of Texas MD Anderson Cancer Center demonstrated that adding metastasis-directed radiation therapy to intermittent hormone therapy improved progression-free survival in patients with oligometastatic prostate cancer. Findings from the multicenter EXTEND trial were...
Response-Adapted Ultra–Low Dose Radiation Achieves Complete Response in Majority of Patients With Orbital Indolent B-Cell Lymphomas
Using a novel response-adapted ultra–low dose radiation therapy strategy, researchers at The University of Texas MD Anderson Cancer Center observed a 90% complete response rate in patients with orbital indolent B-cell lymphomas. Results were presented by Pinnix et al at the 2022 American Society...
Medical Physicist Consults May Help Reduce Patient Anxiety and Increase Satisfaction With Radiation Care
Meeting with a medical physicist who can explain how radiation therapy is planned and delivered may reduce patient anxiety and increase patient satisfaction throughout the treatment process, according to a new study published by Burmeister et al in the International Journal of Radiation Oncology •...
YES Oklahoma Project Created to Improve Representation of Native Americans in Cancer Research
The National Cancer Institute of the National Institutes of Health (NIH) has awarded the University of Oklahoma (OU) an expected $2 million over 5 years to develop a program to improve representation of Oklahoma Native American students in biomedical and cancer research. “American Indian...
Providing a Tailored Approach to Prostate Cancer Care for Gay and Bisexual Men
It is estimated that one in eight men will be diagnosed with prostate cancer in his lifetime. The disease is so prevalent, and other than skin cancer, it is the most common cancer diagnosed in American men. According to the American Cancer Society, this year, about 268,490 new cases of prostate...
Novel Selective Estrogen Receptor Degraders in Advanced Breast Cancer: Use of Elacestrant in the Phase III EMERALD Trial
Endocrine therapy is the foundation of first-line therapy in most patients with hormone receptor–positive, HER2-negative metastatic breast cancer. Many of these patients respond to endocrine therapy but eventually become resistant to it through both intrinsic and acquired resistance mechanisms....
Elacestrant Improves Progression-Free Survival vs Standard Endocrine Therapy in Previously Treated Estrogen Receptor–Positive, HER2-Negative Advanced Breast Cancer
As reported in the Journal of Clinical Oncology by François-Clément Bidard, MD, PhD, of the Institut Curie, Paris and Saint Cloud, and colleagues, the phase III EMERALD trial has shown prolonged progression-free survival with the oral selective estrogen receptor degrader elacestrant vs standard...
Richter Transformation Remains Challenging, but Better Treatments Are on the Horizon
Richter transformation, usually a diffuse large B-cell lymphoma developing in a person with CLL, remains a challenging entity, but novel regimens look promising, as described at the 2022 Pan Pacific Lymphoma Conference by Matthew S. Davids, MD, MMSc, Associate Professor of Medicine at Harvard...
Negative Phase III Trials May Dampen Enthusiasm for Immunotherapy in the Adjuvant Setting in Kidney Cancer
Three negative phase III trials presented at the European Society for Medical Oncology (ESMO) Congress 2022 may dampen enthusiasm for immunotherapy as adjuvant therapy for renal cell carcinoma (RCC). None of the three trials—CheckMate 914, IMmotion010, and PROSPER—met its primary endpoint.1-3 The...
Why Are Young Adult Women Developing Later-Stage, More Aggressive Breast Cancer Than Older Women?
It has been well documented that breast cancer is the most common malignancy in adolescent and young adult (AYA) women aged 15 to 39 years, accounting for 30% of cancers among this population.1 In addition, 5.6% of all invasive breast cancers occur in AYA women.1 A presentation by Rebecca H....
IPSOS Trial: Platinum-Ineligible Patients With NSCLC May Gain Survival Benefit From Atezolizumab Therapy
In platinum-ineligible patients with advanced non–small cell lung cancer (NSCLC), first-line treatment with the PD-L1 checkpoint inhibitor atezolizumab improved overall survival by an absolute value of about 1 month but almost doubled the rate of 2-year overall survival compared with chemotherapy...
Prophylactic Radiation for Asymptomatic Bone Metastases May Reduce Pain and Extend Survival
Treating high-risk, asymptomatic bone metastases with radiation may reduce painful complications and hospitalizations and possibly extend overall survival in people whose cancer has spread to multiple sites, a phase II clinical trial suggests. Results of the multicenter, randomized trial were...
Small First-in-Human Trial Investigates FLASH Proton Radiotherapy for Patients With Bone Metastases
FLASH radiation treatment—which delivers therapeutic doses of radiation in a fraction of a second—may be a potential treatment for tough-to-kill tumors, a first-in-human study in a small number of people with bone cancer suggests. The technology, previously tested in animals, was shown to be as...
Adding SBRT to Sorafenib May Improve Survival and Time to Disease Progression in Patients With Advanced HCC
Adding stereotactic body radiation therapy (SBRT) to systemic therapy with sorafenib for patients with advanced hepatocellular carcinoma (HCC) may extend overall survival and delay tumor progression without compromising patients’ quality of life, findings from the randomized phase III NRG...
Multicenter Study Sheds Light on Features of Invasive Lobular Carcinoma
A multicenter analysis of patients with invasive lobular carcinoma—the second most common histologic subtype of invasive breast cancer in the United States—showed that, despite its prevalence, invasive lobular carcinoma was detected later with worse outcomes vs invasive ductal carcinoma and had...
Use of Remote Interventions Increased Adherence to Cancer Screenings Among Women in Rural Areas
Studies show that rural populations experience greater cancer disparities across the cancer control continuum—from prevention and incidence to survivorship and mortality—compared with their urban counterparts. Those living in rural parts of the United States also tend to have lower cancer screening ...
Intensive Chemoresection With Mitomycin to Reduce the Need for Surgical Procedures in Patients With Recurrent Non–Muscle-Invasive Bladder Cancer
In a Danish study (DaBlaCa-13) reported in the Journal of Clinical Oncology, Lindgren et al found that short-term intensive chemoresection with mitomycin reduced the need for surgical procedures in patients with recurrent non–muscle-invasive bladder cancer. Study Details The trial was conducted at...
Study Examines Efficacy, Cost of FIT vs Multitarget Stool DNA Testing for Colorectal Cancer Screening
Commercially available noninvasive screening tests for colorectal cancer—the fecal immunochemical test (FIT) and the Cologuard multitarget stool DNA test—are equally effective for screening patients with early-stage colorectal cancer. However, FIT costs about one-fifth of the multitarget stool DNA...
Timely Surveillance With Chest Imaging May Benefit Patients With Metastatic Colorectal Cancer
Patients with colorectal cancer who have certain clinical characteristics may benefit from more frequent chest imaging to help identify and target cancer that has metastasized to the lungs, according to a new study presented at the 2022 Scientific Forum of the American College of Surgeons Clinical...
Single-Dose Carboplatin Plus Involved-Node Radiotherapy in Stage IIA/IIB Seminoma
In a Swiss/German phase II trial (SAKK 01/10) reported in The Lancet Oncology, Papachristofilou et al found that a single dose of carboplatin followed by involved-node radiotherapy narrowly missed the target 3-year progression-free survival rate in patients with stage IIA or IIB seminoma. As...
First-Line Nivolumab/Ipilimumab vs Chemotherapy in Metastatic NSCLC Without EGFR or ALK Alterations: 5-Year Survival
As reported in the Journal of Clinical Oncology by Julie R. Brahmer, MD, MSc, FASCO, and colleagues, a 5-year analysis of the phase III CheckMate 227 trial showed improvement in overall survival with first-line nivolumab/ipilimumab vs platinum-doublet chemotherapy, at ≥ 3 years after cessation of...
Prevalence of and Risks for Thoracic Soft-Tissue Sarcomas in Breast Cancer Survivors
In a retrospective cohort study reported in The Lancet Oncology, Veiga et al found that receipt of radiotherapy was the strongest risk factor for development of thoracic soft-tissue sarcomas in U.S. breast cancer survivors; both hypertension and diabetes were significant risk factors for...
David Cescon, MD, PhD, Comments on the MONALEESA Analyses
David Cescon, MD, PhD, Clinician Scientist at the Princess Margaret Cancer Centre in Toronto, Canada, was the invited discussant of the two MONALEESA analyses.1,2 He noted that the most recent overall survival analysis, presented at the European Society for Medical Oncology (ESMO) Congress 2021,...
MONALEESA Analyses Show Widespread Benefit for Ribociclib in Hormone Receptor–Positive, HER2-Negative Breast Cancer
Further analyses of the MONALEESA metastatic breast cancer trials have shown that the benefit of ribociclib plus endocrine therapy in the first-line setting extends to most intrinsic molecular subtypes and is consistent across multiple subgroups. The studies were presented at the 2021 San Antonio...
